TBIO

New technology has potential to accelerate timelines for therapeutic research and drug development Telesis Bio Inc. (OTC:TBIO), a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced a new license agreement with Regeneron Pharmaceuticals, Inc. to deploy Telesis Bio's revolutionary Gibson SOLA™ platform at its R&D core facilities. This will help Regeneron adopt automated, high-throughput, on-demand gene synthesis in their own labs. Using Gibson SOLA at scale is intended to contribute to an agile and efficient approach to biologics discovery. The Gibson SOLA platform has been shown to e

Telesis Bio, a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced that it has entered into a convertible preferred stock purchase agreement (the Purchase Agreement) to sell shares of a new series of convertible preferred stock in a private placement. The financing was led by Novalis LifeSciences and Northpond Ventures and is expected to result in gross proceeds to the Company of up to approximately $21 million. The Company's recently launched proprietary next-generation enzymatic synthesis platform, Gibson SOLA™, allows customers to take full control of their nucleic acid supply-chain,

15-12G - Telesis Bio Inc. (0001850079) (Filer)

EFFECT - Telesis Bio Inc. (0001850079) (Filer)

EFFECT - Telesis Bio Inc. (0001850079) (Filer)

POS AM - Telesis Bio Inc. (0001850079) (Filer)

POS AM - Telesis Bio Inc. (0001850079) (Filer)

S-8 POS - Telesis Bio Inc. (0001850079) (Filer)

S-8 POS - Telesis Bio Inc. (0001850079) (Filer)

S-8 POS - Telesis Bio Inc. (0001850079) (Filer)

8-K - Telesis Bio Inc. (0001850079) (Filer)

SC 13G/A - Telesis Bio Inc. (0001850079) (Subject)

10-Q - Telesis Bio Inc. (0001850079) (Filer)

SC 13D/A - Telesis Bio Inc. (0001850079) (Subject)

SC 13D/A - Telesis Bio Inc. (0001850079) (Subject)

8-K - Telesis Bio Inc. (0001850079) (Filer)

SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- A new partnership between Telesis Bio and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, will create efficient and scalable biofoundries, delivering solutions for sustainable and rapid on-premise synthesis of DNA. This innovative approach enabled by Telesis Bio's Gibson SOLA enzymatic reagent platform running on Beckman Coulter Life Sciences automation to ensures rapid, reliable, and highly scalable production of extremely high-fidelity DNA, empowering researchers to achieve greater productivity and innovation in a wide array of discovery applications. The collaboration integrates Telesis Bio's Gibson

25 - Telesis Bio Inc. (0001850079) (Filer)

8-K - Telesis Bio Inc. (0001850079) (Filer)

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO) ("Telesis" or the "Company"), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis technology in their own lab, announced today that it has notified the Nasdaq Stock Market LLC ("Nasdaq") of its decision to delist the Company's shares of common stock, par value $0.001 per share (the "Common Stock") and deregister the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Telesis intends to file a Form 25 with the Securities and Exchange Commission (the "SEC")

8-K - Telesis Bio Inc. (0001850079) (Filer)

8-K - Telesis Bio Inc. (0001850079) (Filer)

8-K - Telesis Bio Inc. (0001850079) (Filer)

10-Q - Telesis Bio Inc. (0001850079) (Filer)

8-K - Telesis Bio Inc. (0001850079) (Filer)